首页 › 基金 › KVP Capital Advisors, LP › NKTR
KVP Capital Advisors, LP 对 NKTR 的持仓历史
NEKTAR THERAPEUTICS · 医疗保健
KVP Capital Advisors, LP 在 Q3 2026 的 13F 申报中披露持有 NKTR(NEKTAR THERAPEUTICS)26,900 股,市值约 US$1.6M,约占其申报组合的 1.33%,在其申报持仓中市值排名第 25 位。 KVP Capital Advisors, LP 最近 4 个申报季度中有 4 个季度披露了 NKTR 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
KVP Capital Advisors, LP 对 NKTR 的持仓演变
KVP Capital Advisors, LP 于 Q4 2025 首次披露 NKTR 持仓:26,900 股(约 US$1.1M)。 该持仓在 Q1 2026 达到峰值 26,900 股,市值约 US$1.9M。 在 4 次申报中,KVP Capital Advisors, LP 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 26,900 股、市值约 US$1.6M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 26.90K | $1.14M | 新进 |
| Q1 2026 | 26.90K | $1.94M | 持有 |
| Q2 2026 | 26.90K | $1.88M | 持有 |
| Q3 2026 | 26.90K | $1.63M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 NKTR 与 13F 数据
NKTR(NEKTAR THERAPEUTICS)属于医疗保健行业。我们追踪的基金中还有 57 只申报持有 NKTR,申报仓位最大的包括:Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 NKTR 的基金
- Two Seas Capital LP 3.35M 股 · $202.58M · Q3 2026
- BVF INC/IL 2.39M 股 · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M 股 · $69.81M · Q2 2026
- Prosight Management, LP 785.00K 股 · $47.53M · Q3 2026
- ARMISTICE CAPITAL, LLC 700.00K 股 · $42.38M · Q3 2026
- BRAIDWELL LP 473.62K 股 · $33.06M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K 股 · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K 股 · $22.23M · Q2 2026
- 22NW, LP 281.12K 股 · $17.02M · Q3 2026
- ADAR1 Capital Management, LLC 258.18K 股 · $15.63M · Q3 2026
- SEVEN GRAND MANAGERS, LLC 240.00K 股 · $14.53M · Q3 2026
- Bronte Capital Management Pty Ltd. 202.06K 股 · $12.23M · Q3 2026
更多关于 KVP Capital Advisors, LP
常见问题
How long has KVP Capital Advisors, LP held NKTR?
KVP Capital Advisors, LP has disclosed NKTR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is KVP Capital Advisors, LP's current position in NKTR?
As of Q3 2026, KVP Capital Advisors, LP holds 26.90K shares of NKTR (NEKTAR THERAPEUTICS), valued at $1.63M, representing 1.33% of its reported portfolio and ranking #25.
Has KVP Capital Advisors, LP been buying or selling NKTR?
In the latest 13F filing (Q3 2026), KVP Capital Advisors, LP held unchanged its position in NKTR. The position peaked in Q1 2026 at 26.90K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.